Journals / Journal of Neurological Sciences (Turkish) / 2008 / Cilt: 25 - Sayı: 2

A psychotic attack after steroid therapy in clinically isolated syndrome manifesting as optic neuritis

Optik nörit şeklinde ortaya çıkan klinik izole sendromlu bir hastada steroid tedavisi sonrası psikotik atak

Pages
148–153
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We consider that it's important to take the psychiatric history before the steroid therapy and to reevaluate the necessity of the high dose steroid therapy and to choose the minimum dosage and period for the patients that have psychotic attack history.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Corticosteroids have been widely used in attacks of Multiple Sclerosis (MS) and Clinically Isolated Syndromes but may rarely cause psychiatric manifestations, such as depression, mania, psychosis and delirium.
📊
Key Findings & Data:Case Presentation: A 28 year-old housewife who had presented with a sudden blurring of vision had been diagnosed MS and applied 1000 mg/day intravenous methylprednisolone therapy for 10 days as a MS attack therapy in another hospital 20 days ago.
💡
Conclusion & Impact:We consider that it's important to take the psychiatric history before the steroid therapy and to reevaluate the necessity of the high dose steroid therapy and to choose the minimum dosage and period for the patients that have psychotic attack history.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Corticosteroids have been widely used in attacks of Multiple Sclerosis (MS) and Clinically Isolated Syndromes but may rarely cause psychiatric manifestations, such as depression, mania, psychosis and delirium. Steroid-induced mood disorders have common clinical features, such as subacute onset, manic predominance and having psychotic history. Case Presentation: A 28 year-old housewife who had presented with a sudden blurring of vision had been diagnosed MS and applied 1000 mg/day intravenous methylprednisolone therapy for 10 days as a MS attack therapy in another hospital 20 days ago. One week after the steroid therapy she was taken to our outpatient clinic with paranoia, aggressive behaviors and disorientation. Neurological examination was normal except right optic neuritis. Brain MRI revealed periventricular and cerebellar demyelination. In her medical history she had behavioral pathologies as paranoia, aggression, visual hallucinations 5 years ago and her symptoms recovered without any psychiatric treatment less than one month. She didn't have another attack except optic neuritis, therefore we considered her diagnosis as Clinically Isolated Syndrome. After psychiatry consultation olanzapine at 20 mg/day was initiated and psychiatric excitations were taken under control. Conclusions: Intravenous methylprednisolone is usually administered in 0,5-1 gr/day dosage for 3-10 days in MS. It is considered that there's no significant difference between the administration periods in terms of the efficacy. We consider that it's important to take the psychiatric history before the steroid therapy and to reevaluate the necessity of the high dose steroid therapy and to choose the minimum dosage and period for the patients that have psychotic attack history.

Özet

Giriş: Kortikosteroidler yaygın olarak Multipl Skleroz'da (MS) atak tedavisinde ve Klinik İzole Sendromlarda kullanılmaktadır ancak nadiren depresyon, mani, psikoz ve deliryum gibi psikiyatrik tablolara neden olurlar. Steroidlerin sebep olduğu duygudurum bozukluklarının ortak klinik özellikleri arasında subakut başlangıç, manik predominans ve öyküde psikotik özellikler bulunur. Olgu sunumu: 28 yaşında, kadın, evhanımı. Yirmi gün önce ani başlayan sağ gözde bulanık görme yakınması nedeniyle müracaat ettiği merkez tarafından MS tanısı ile, 10 gün boyunca 1000 mg/gün intravenöz metilprednizolon tedavisi uygulanmış. Steroid tedavisinin tamamlanmasından 1 hafta sonra anlamsız kuşkuculuk, saldırganlık, zaman ve yer oryantasyonun kaybolmasıyla polikliniğimize getirildi. Nörolojik muayenesinde sağ gözde optik nörit ile uyumlu bulgular haricinde patolojik bulgu saptanmadı. Beyin MR'da periventriküler beyaz cevher ve sol serebellar hemisferde demiyelinizan plaklar saptandı. Kendisi ve ailesi ile yapılan görüşmeden demyelinizan hastalığı düşündürecek yakınmalar ile seyreden ataklarının olmadığı ve beş yıl önce kuşkuculuk, saldırganlık, görsel halüsinasyonlar gibi davranış patolojileri sergilediği, herhangi bir tıbbi yardım almadan bu semptomların yaklaşık bir ay içinde gerilediği ve tamamen düzeldiği öğrenilen hasta Klinik İzole Sendrom olarak kabul edildi. Psikiyatri konsultasyonu sonucunda olanzapin 20 mg/gün tedavisi başlandı ve eksitasyonları kontrol altına alındı. Sonuç: MS'de intravenöz metilprednizolon genellikle 0,5-1 gr/gün olarak ve 3-10 gün süreyle uygulanmakta ve etkinlik açısından değişken sürenin önemli fark yaratmadığı bilinmektedir. Tedavi öncesi psikiyatrik öykünün alınması ve geçmişte psikotik atak öyküsü olan hastalarda yüksek doz steroid tedavisi gerekliliğinin tekrar değerlendirilmesi ve bu hastalarda tedavide mümkün olan en düşük doz ve sürenin seçilmesinin önemli olduğunu düşünmekteyiz.

🔖

Cite This Article

BEK, V. S., YETKİN, S., HAMAMCIOĞLU, K., GENÇ, G., ÖNAL, M. R., DEMİRKAYA, Ş., ODABAŞI, Z. (2022). A psychotic attack after steroid therapy in clinically isolated syndrome manifesting as optic neuritis. Journal of Neurological Sciences (Turkish), Cilt: 25 - Sayı: 2, 148–153. https://ajindex.com/articles/565556

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, Francis DA, Perkin GD, Rudge P, Swash M, Katifi H, Farmer S, Frankel J. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet. 1997
  2. 6 2) Bräunig P, Bleistein J. Cortisone-induced psychoses Nervenarzt. 1988 Oct
  3. 59(10):596-602. 3) Brown ES, Chamberlain W, Dhanani N, Paranjpe P, Carmody TJ, Sargeant M. An open-label trial of olanzapine for corticosteroid-induced mood symptoms. J Affect Disord. 2004 Dec
  4. 83(2-3):277-81. 4) Brown ES, Chandler PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. Prim Care Companion J Clin Psychiatry. 2001 Feb
  5. 3(1):17-21. 5) Brown ES, Khan DA, Nejtek VA. The psychiatric side effects of corticosteroids. Ann Allergy Asthma Immunol. 1999 Dec
  6. 83(6 Pt 1):495-503 6) Brown ES, Suppes T. Mood symptoms during corticosteroid therapy: a review Harv Rev Psychiatry. 1998
  7. 46 7) Chong SA, Ko SM. Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiat. 1997
  8. 1 8) Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Progr Neuro-Psychopharmacol Biol Psychiat 2004
  9. 4 9) Habek M, Brinar M, Brinar VV, Poser CM. Psychiatric manifestations of multiple sclerosis and acute disseminated encephalomyelitis. Clin Neurol Neurosurg. 2006 Mar
  10. 108(3):290-4. Epub 2005 Dec 20. 10) Idiman E, Akdal G, Alkın T, Yener GG, Baklan B. The co-occurrence of bipolar disorder and multiple sclerosis. Nörolojik Bilimler Dergisi 1999:16.2 11) Idiman E, Gülay Z, Doganer I et al. Multiple sclerosis and affective disorder HLA class I and class II antigens and MRI. J Neurol 1994
  11. 241 (Suppl I): S140. 12) Iñiguez C, Campos R, Larrodé P, Mauri JA, Morales F. Steroid treatment of acute psychosis associated with multiple sclerosis Rev Neurol. 2000
  12. 4 13) Jongen PJ. Psychiatric onset of multiple sclerosis. J Neurol Sci. 2006 Jun 15
  13. 245(1-2):59-62. Epub 2006 Apr 24. 14) Mendhekar DN, Mehta R, Puri V. Successful steroid therapy in multiple sclerosis presented as acute psychosis. J Assoc Physicians India. 2004 Jun
  14. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry. 1987 May
  15. 50(5):511-6. 16) Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations